Company intelligence / Profile preview

Corsair International

Sunnyvale, California, USAflycorsair.com ↗

Ownership: Private
Development stage: Commercial

Overview

The lead program—a once-daily transdermal prodrug patch delivering treprostinil—is completing preclinical development with plans to enter clinical trials. The approach aims to improve safety and convenience over current prostacyclin therapies by avoiding infusion-related complications and providing consistent blood levels via skin absorption.

Therapeutic areas: Cardiovascular
Modalities: Small moleculeProdrug therapyTransdermal drug delivery systemPatch-based drug delivery device
Industry: Biotech

Partnerships

United Therapeutics

Beyond the preview

Go deeper on Corsair International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corsair International.

Explore the full profile